TRIL insider filings

Trillium Therapeutics Inc. — 36 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2021-11-19. Screen TRIL transaction legs live →

Insider transaction summary — last 90 days

No insider filings (Forms 3/4/5) for TRIL between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.

Recent insider filings — Trillium Therapeutics Inc.

FiledFormInsiderReported transactionsSource
2021-11-194Harrison Rosemary — See RemarksDisposition to issuer (D): 75 · Disposition to issuer (D): 180,000 (derivative) @ $0EDGAR
2021-11-194Parsons James T. — Chief Financial OfficerDisposition to issuer (D): 180,000 (derivative) @ $0 · Disposition to issuer (D): 94,792 (derivative) @ $0 · Disposition to issuer (D): 59,896 (derivative) @ $0 · Disposition to issuer (D): 5,761 (derivative) @ $0 · Disposition to issuer (D): 36,204 (derivative) @ $0 · Disposition to issuer (D): 24,390 (derivative) @ $0 · +2 moreEDGAR
2021-11-194Looker Benjamin — General CounselDisposition to issuer (D): 190,000 (derivative) @ $0EDGAR
2021-11-194MACKEY CATHERINE J — DirectorDisposition to issuer (D): 67,000 (derivative) @ $0EDGAR
2021-11-194Bruns Ingmar — Chief Medical OfficerDisposition to issuer (D): 400,000 (derivative) @ $0EDGAR
2021-11-194Petrova Penka — Chief Development OfficerDisposition to issuer (D): 38,808 (derivative) @ $0 · Disposition to issuer (D): 4,574 (derivative) @ $0 · Disposition to issuer (D): 49,480 (derivative) @ $0 · Disposition to issuer (D): 83,960 (derivative) @ $0 · Disposition to issuer (D): 140,000 (derivative) @ $0EDGAR
2021-11-194Uger Robert — Chief Scientific OfficerDisposition to issuer (D): 102,083 (derivative) @ $0 · Disposition to issuer (D): 58,333 (derivative) @ $0 · Disposition to issuer (D): 5,260 (derivative) @ $0 · Disposition to issuer (D): 23,473 (derivative) @ $0 · Disposition to issuer (D): 29,073 (derivative) @ $0 · Disposition to issuer (D): 250,000 (derivative) @ $0EDGAR
2021-11-194TAYTON-MARTIN HELEN KATRINA — DirectorDisposition to issuer (D): 40,000 (derivative) @ $0 · Disposition to issuer (D): 498,294.29 (derivative)EDGAR
2021-11-194Skvarka Jan — President and CEO, DirectorDisposition to issuer (D): 197,000 (derivative) @ $0 · Disposition to issuer (D): 1,162,500 (derivative) @ $0 · Disposition to issuer (D): 600,000 (derivative) @ $0EDGAR
2021-11-194Walker Paul Edward — DirectorDisposition to issuer (D): 5,736,363 @ $0 · Disposition to issuer (D): 850,000 (derivative) @ $0 · Disposition to issuer (D): 6,750,000 (derivative) @ $0 · Disposition to issuer (D): 5,400,000 (derivative) @ $0 · Disposition to issuer (D): 40,000 (derivative) @ $0EDGAR
2021-11-194Kamarck Michael E. — DirectorDisposition to issuer (D): 67,000 (derivative) @ $0EDGAR
2021-11-194Pucci Paolo — DirectorDisposition to issuer (D): 67,000 (derivative) @ $0EDGAR
2021-11-194Myers Scott Dunseth — DirectorDisposition to issuer (D): 67,000 (derivative) @ $0EDGAR
2021-11-194BESHAR LUKE M — DirectorDisposition to issuer (D): 40,000 (derivative) @ $0 · Disposition to issuer (D): 6,666 (derivative) @ $0 · Disposition to issuer (D): 547,656.26 (derivative)EDGAR
2021-07-094Uger Robert — Chief Scientific OfficerOption exercise (M): 3,646 @ $0.30 · Sale (S): 3,646 @ $9 · Option exercise (M): 3,646 (derivative) @ $0EDGAR
2021-07-024MACKEY CATHERINE J — DirectorGrant/award (A): 67,000 (derivative) @ $0EDGAR
2021-06-094Uger Robert — Chief Scientific OfficerOption exercise (M): 3,646 @ $0.32 · Sale (S): 3,646 @ $8.27 · Option exercise (M): 3,646 (derivative) @ $0EDGAR
2021-05-134Skvarka Jan — President and CEO, DirectorOption exercise (M): 87,500 @ $0.45 · Option exercise (M): 19,198 @ $0.31 · Sale (S): 106,698 @ $9.20 · Option exercise (M): 23,802 @ $0.31 · Sale (S): 23,802 @ $9.24 · Option exercise (M): 87,500 (derivative) @ $0 · +2 moreEDGAR
2021-05-114Uger Robert — Chief Scientific OfficerOption exercise (M): 3,646 @ $0.31 · Sale (S): 3,646 @ $9.30 · Option exercise (M): 3,646 (derivative) @ $0EDGAR
2021-05-054Looker Benjamin — General CounselGrant/award (A): 190,000 (derivative) @ $0EDGAR
2021-05-054Myers Scott Dunseth — DirectorGrant/award (A): 67,000 (derivative) @ $0EDGAR
2021-04-094Uger Robert — Chief Scientific OfficerOption exercise (M): 3,646 @ $0.30 · Sale (S): 3,646 @ $10.82 · Option exercise (M): 3,646 (derivative) @ $0EDGAR
2021-04-094Petrova Penka — Chief Development OfficerOption exercise (M): 2,708 @ $0.30 · Option exercise (M): 2,604 @ $3.36 · Sale (S): 5,312 @ $11.09 · Option exercise (M): 2,708 (derivative) @ $0 · Option exercise (M): 2,604 (derivative) @ $0EDGAR
2021-03-154Uger Robert — Chief Scientific OfficerOption exercise (M): 2,917 @ $3.39 · Sale (S): 2,917 @ $11.97 · Option exercise (M): 2,917 (derivative) @ $0EDGAR
2021-03-124Petrova Penka — Chief Development OfficerOption exercise (M): 2,708 @ $0.30 · Option exercise (M): 2,604 @ $3.35 · Sale (S): 5,312 @ $11.08 · Option exercise (M): 2,708 (derivative) @ $0 · Option exercise (M): 2,604 (derivative) @ $0EDGAR
2021-03-104Uger Robert — Chief Scientific OfficerOption exercise (M): 3,646 @ $0.30 · Sale (S): 3,646 @ $10.11 · Option exercise (M): 3,646 (derivative) @ $0EDGAR
2021-02-104Petrova Penka — Chief Development OfficerOption exercise (M): 2,708 @ $0.30 · Option exercise (M): 2,604 @ $3.31 · Sale (S): 5,312 @ $12.65 · Option exercise (M): 508 @ $9.62 · Sale (S): 508 @ $14.17 · Option exercise (M): 2,708 (derivative) @ $0 · +2 moreEDGAR
2021-02-104Uger Robert — Chief Scientific OfficerOption exercise (M): 3,646 @ $0.30 · Option exercise (M): 2,917 @ $3.31 · Sale (S): 6,563 @ $12.65 · Option exercise (M): 584 @ $9.62 · Sale (S): 584 @ $14.12 · Option exercise (M): 3,646 (derivative) @ $0 · +2 moreEDGAR
2021-01-154Skvarka Jan — President and CEO, DirectorOption exercise (M): 5,419 @ $0.42 · Sale (S): 5,419 @ $15.04 · Option exercise (M): 19,581 @ $0.43 · Sale (S): 19,581 @ $15.03 · Option exercise (M): 5,419 (derivative) @ $0 · Option exercise (M): 19,581 (derivative) @ $0EDGAR
2021-01-134Uger Robert — Chief Scientific OfficerOption exercise (M): 584 @ $9.57 · Sale (S): 584 @ $15.20 · Option exercise (M): 584 (derivative) @ $0EDGAR
2021-01-134Petrova Penka — Chief Development OfficerOption exercise (M): 508 @ $9.57 · Sale (S): 508 @ $15.21 · Option exercise (M): 508 (derivative) @ $0EDGAR
2021-01-124Parsons James T. — Chief Financial OfficerOption exercise (M): 8,505 @ $7.24 · Sale (S): 8,505 @ $15.79 · Option exercise (M): 8,505 (derivative) @ $0EDGAR
2021-01-124Uger Robert — Chief Scientific OfficerOption exercise (M): 5,600 @ $11.01 · Sale (S): 5,600 @ $15.82 · Option exercise (M): 2,917 @ $3.33 · Sale (S): 2,917 @ $15.51 · Option exercise (M): 5,600 (derivative) @ $0 · Option exercise (M): 2,917 (derivative) @ $0EDGAR
2021-01-124Petrova Penka — Chief Development OfficerOption exercise (M): 2,604 @ $3.33 · Sale (S): 2,604 @ $15.50 · Option exercise (M): 2,604 (derivative) @ $0EDGAR
2021-01-114Petrova Penka — Chief Development OfficerOption exercise (M): 2,708 @ $0.30 · Sale (S): 2,708 @ $14.71 · Option exercise (M): 2,708 (derivative) @ $0EDGAR
2021-01-114Uger Robert — Chief Scientific OfficerOption exercise (M): 3,646 @ $0.30 · Sale (S): 3,646 @ $14.75 · Option exercise (M): 3,646 (derivative) @ $0EDGAR

Recent 8-K events — Trillium Therapeutics Inc.

Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →

FiledFormItems reportedSource
2021-11-178-K2.01 — Completion of Acquisition or Disposition of Assets
3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
3.03 — Material Modification to Rights of Security Holders
5.01 — Changes in Control of Registrant
5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2021-11-168-K8.01 — Other EventsEDGAR
2021-10-298-K8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2021-10-278-K5.07 — Submission of Matters to a Vote of Security Holders
7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2021-10-208-K8.01 — Other EventsEDGAR
2021-10-158-K8.01 — Other EventsEDGAR
2021-10-138-K8.01 — Other EventsEDGAR
2021-08-238-K1.01 — Entry into a Material Definitive Agreement
5.01 — Changes in Control of Registrant
7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2021-08-138-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2021-06-308-K5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
9.01 — Financial Statements and Exhibits
EDGAR
Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?ticker=TRIL returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs